^
Association details:
| Biomarker: | FGFR2-ERC1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
Published date:
06/10/2022
Excerpt:
We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy....Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion...Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months.
DOI:
https://doi.org/10.2147/OTT.S364566
